Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

LBA-004Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC).

Argilés G, Saro J, Segal NH, Melero I, Ros W, Marabelle A, Rodriguez ME, Albanell J, Calvo E, Moreno V, Cleary JM, Eder P, Paz-Ares L, Hurwitz H, Bacac M, Perro M, Bouseida S, Sandoval F, Sabanes Bove D, Sreckovic S, Jamois C, Silva A, Klein C, Umana P, Karanikas V, Tabernero J.

Ann Oncol. 2017 Jun 1;28(suppl_3). doi: 10.1093/annonc/mdx302.003. No abstract available.

PMID:
30052786
2.

CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.

Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, Diggelmann S, Limani F, Schlenker R, Hüsser T, Richter W, Bray-French K, Hinton H, Giusti AM, Freimoser-Grundschober A, Lariviere L, Neumann C, Klein C, Umaña P.

Clin Cancer Res. 2018 May 1. doi: 10.1158/1078-0432.CCR-18-0455. [Epub ahead of print]

PMID:
29716920
3.

The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.

Palazzo A, Herter S, Grosmaire L, Jones R, Frey CR, Limani F, Bacac M, Umana P, Oldham RJ, Marshall MJE, Cox KL, Turaj AH, Cragg MS, Klein C, Carter MJ, Tannheimer S.

J Immunol. 2018 Apr 1;200(7):2304-2312. doi: 10.4049/jimmunol.1700323. Epub 2018 Feb 16.

4.

GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity.

Herter S, Herting F, Muth G, van Puijenbroek E, Schlothauer T, Ferrara C, Brady K, Lang S, Bacac M, Mössner E, Umana P, Klein C.

Haematologica. 2018 Feb;103(2):e78-e81. doi: 10.3324/haematol.2017.178996. Epub 2017 Oct 27. No abstract available.

5.

Combination therapy with the type II anti-CD20 antibody obinutuzumab.

Klein C, Bacac M, Umana P, Fingerle-Rowson G.

Expert Opin Investig Drugs. 2017 Oct;26(10):1145-1162. doi: 10.1080/13543784.2017.1373087. Review.

PMID:
28845710
6.

An Immune Atlas of Clear Cell Renal Cell Carcinoma.

Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D, Bacac M, Ries CH, Ailles L, Jewett MAS, Moch H, van den Broek M, Beisel C, Stadler MB, Gedye C, Reis B, Pe'er D, Bodenmiller B.

Cell. 2017 May 4;169(4):736-749.e18. doi: 10.1016/j.cell.2017.04.016.

7.

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.

Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, Lang S, Roemmele M, Hofer T, van Puijenbroek E, Wittig D, Moser S, Ast O, Brünker P, Gorr IH, Neumann S, de Vera Mudry MC, Hinton H, Crameri F, Saro J, Evers S, Gerdes C, Bacac M, van Dongen G, Moessner E, Umaña P.

Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402X.2016.1277306. eCollection 2017.

8.

Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.

Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, Lipp S, Merino J, Prosper F, Emde M, Delon C, Latzko M, Gianotti R, Lüoend R, Murr R, Hosse RJ, Harnisch LJ, Bacac M, Fauti T, Klein C, Zabaleta A, Hillengass J, Cavalcanti-Adam EA, Ho AD, Hundemer M, San Miguel JF, Strein K, Umaña P, Hose D, Paiva B, Vu MD.

Cancer Cell. 2017 Mar 13;31(3):396-410. doi: 10.1016/j.ccell.2017.02.002. Epub 2017 Mar 2.

9.

A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents.

Herter S, Morra L, Schlenker R, Sulcova J, Fahrni L, Waldhauer I, Lehmann S, Reisländer T, Agarkova I, Kelm JM, Klein C, Umana P, Bacac M.

Cancer Immunol Immunother. 2017 Jan;66(1):129-140. doi: 10.1007/s00262-016-1927-1. Epub 2016 Nov 17.

10.

CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors.

Bacac M, Klein C, Umana P.

Oncoimmunology. 2016 Jun 24;5(8):e1203498. doi: 10.1080/2162402X.2016.1203498. eCollection 2016 Aug.

11.

Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB.

Dudal S, Hinton H, Giusti AM, Bacac M, Muller M, Fauti T, Colombetti S, Heckel T, Giroud N, Klein C, Umaña P, Benincosa L, Bachl J, Singer T, Bray-French K.

J Immunother. 2016 Sep;39(7):279-89. doi: 10.1097/CJI.0000000000000132.

PMID:
27404941
12.

In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing.

Lehmann S, Perera R, Grimm HP, Sam J, Colombetti S, Fauti T, Fahrni L, Schaller T, Freimoser-Grundschober A, Zielonka J, Stoma S, Rudin M, Klein C, Umana P, Gerdes C, Bacac M.

Clin Cancer Res. 2016 Sep 1;22(17):4417-27. doi: 10.1158/1078-0432.CCR-15-2622. Epub 2016 Apr 26.

13.

Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor.

Schreiner J, Thommen DS, Herzig P, Bacac M, Klein C, Roller A, Belousov A, Levitsky V, Savic S, Moersig W, Uhlenbrock F, Heinzelmann-Schwarz VA, Umana P, Pisa P, von Bergwelt-Baildon M, Lardinois D, Müller P, Karanikas V, Zippelius A.

Oncoimmunology. 2015 Jun 24;5(2):e1062969. eCollection 2016 Feb.

14.

Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).

Herting F, Herter S, Friess T, Muth G, Bacac M, Sulcova J, Umana P, Dangl M, Klein C.

Eur J Haematol. 2016 Nov;97(5):461-470. doi: 10.1111/ejh.12756. Epub 2016 Apr 18.

PMID:
26993060
15.

XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer.

Schanzer JM, Wartha K, Moessner E, Hosse RJ, Moser S, Croasdale R, Trochanowska H, Shao C, Wang P, Shi L, Weinzierl T, Rieder N, Bacac M, Ries CH, Kettenberger H, Schlothauer T, Friess T, Umana P, Klein C.

MAbs. 2016 May-Jun;8(4):811-27. doi: 10.1080/19420862.2016.1160989. Epub 2016 Mar 16.

16.

A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.

Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, Bodmer W, Lehmann S, Hofer T, Hosse RJ, Moessner E, Ast O, Bruenker P, Grau-Richards S, Schaller T, Seidl A, Gerdes C, Perro M, Nicolini V, Steinhoff N, Dudal S, Neumann S, von Hirschheydt T, Jaeger C, Saro J, Karanikas V, Klein C, Umaña P.

Clin Cancer Res. 2016 Jul 1;22(13):3286-97. doi: 10.1158/1078-0432.CCR-15-1696. Epub 2016 Feb 9.

17.

Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy.

Gonzalez-Nicolini V, Herter S, Lang S, Waldhauer I, Bacac M, Roemmele M, Bommer E, Freytag O, van Puijenbroek E, Umaña P, Gerdes CA.

Clin Cancer Res. 2016 May 15;22(10):2453-61. doi: 10.1158/1078-0432.CCR-14-2579. Epub 2015 Nov 18.

18.

Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors.

Thommen DS, Schreiner J, Müller P, Herzig P, Roller A, Belousov A, Umana P, Pisa P, Klein C, Bacac M, Fischer OS, Moersig W, Savic Prince S, Levitsky V, Karanikas V, Lardinois D, Zippelius A.

Cancer Immunol Res. 2015 Dec;3(12):1344-55. doi: 10.1158/2326-6066.CIR-15-0097. Epub 2015 Aug 7.

19.

Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity.

Herter S, Birk MC, Klein C, Gerdes C, Umana P, Bacac M.

J Immunol. 2014 Mar 1;192(5):2252-60. doi: 10.4049/jimmunol.1301249. Epub 2014 Jan 31.

20.

Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.

Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S, Duong MN, Reslan L, Gerdes CA, Friess T, Baer U, Burtscher H, Weidner M, Dumontet C, Umana P, Niederfellner G, Bacac M, Klein C.

Mol Cancer Ther. 2013 Oct;12(10):2031-42. doi: 10.1158/1535-7163.MCT-12-1182. Epub 2013 Jul 19.

21.

Identification of prognostic molecular features in the reactive stroma of human breast and prostate cancer.

Planche A, Bacac M, Provero P, Fusco C, Delorenzi M, Stehle JC, Stamenkovic I.

PLoS One. 2011;6(5):e18640. doi: 10.1371/journal.pone.0018640. Epub 2011 May 18.

22.

Securin and separase modulate membrane traffic by affecting endosomal acidification.

Bacac M, Fusco C, Planche A, Santodomingo J, Demaurex N, Leemann-Zakaryan R, Provero P, Stamenkovic I.

Traffic. 2011 May;12(5):615-26. doi: 10.1111/j.1600-0854.2011.01169.x. Epub 2011 Feb 25.

23.

Metastatic cancer cell.

Bacac M, Stamenkovic I.

Annu Rev Pathol. 2008;3:221-47. doi: 10.1146/annurev.pathmechdis.3.121806.151523. Review.

PMID:
18233952
24.

A mouse stromal response to tumor invasion predicts prostate and breast cancer patient survival.

Bacac M, Provero P, Mayran N, Stehle JC, Fusco C, Stamenkovic I.

PLoS One. 2006 Dec 20;1:e32.

25.

A gene expression signature that distinguishes desmoid tumours from nodular fasciitis.

Bacac M, Migliavacca E, Stehle JC, McKee T, Delorenzi M, Coindre JM, Guillou L, Stamenkovic I.

J Pathol. 2006 Mar;208(4):543-53.

PMID:
16440290
26.

Cocultures of metastatic and host immune cells: selective effects of NAMI-A for tumor cells.

Bacac M, Vadori M, Sava G, Pacor S.

Cancer Immunol Immunother. 2004 Dec;53(12):1101-10.

PMID:
15221285
27.

Intratumoral NAMI-A treatment triggers metastasis reduction, which correlates to CD44 regulation and tumor infiltrating lymphocyte recruitment.

Pacor S, Zorzet S, Cocchietto M, Bacac M, Vadori M, Turrin C, Gava B, Castellarin A, Sava G.

J Pharmacol Exp Ther. 2004 Aug;310(2):737-44. Epub 2004 Apr 9.

28.

Structure-dependent in vitro cytotoxicity of the isomeric complexes [Ru(L)2Cl2] (L= o-tolylazopyridine and 4-methyl-2-phenylazopyridine) in comparison to [Ru(azpy)2Cl2].

Hotze AC, Caspers SE, de Vos D, Kooijman H, Spek AL, Flamigni A, Bacac M, Sava G, Haasnoot JG, Reedijk J.

J Biol Inorg Chem. 2004 Apr;9(3):354-64. Epub 2004 Mar 19.

PMID:
15034769
29.

The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation.

Bacac M, Hotze AC, van der Schilden K, Haasnoot JG, Pacor S, Alessio E, Sava G, Reedijk J.

J Inorg Biochem. 2004 Feb;98(2):402-12.

PMID:
14729322
30.

Automated parallel solid-phase synthesis and anticancer screening of a library of peptide-tethered platinum(II) complexes.

Robillard MS, Bacac M, van den Elst H, Flamigni A, van der Marel GA, van Boom JH, Reedijk J.

J Comb Chem. 2003 Nov-Dec;5(6):821-5.

PMID:
14606811
31.

New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.

Hotze AC, Bacac M, Velders AH, Jansen BA, Kooijman H, Spek AL, Haasnoot JG, Reedijk J.

J Med Chem. 2003 Apr 24;46(9):1743-50.

PMID:
12699392
32.

Analysis of the cytotoxicity of synthetic antimicrobial peptides on mouse leucocytes: implications for systemic use.

Pacor S, Giangaspero A, Bacac M, Sava G, Tossi A.

J Antimicrob Chemother. 2002 Sep;50(3):339-48.

PMID:
12205058
33.

Isolation of a murine metastatic cell line and preliminary test of sensitivity to the anti-metastasis agent NAMI-A.

Pacor S, Vadori M, Vita F, Bacac M, Soranzo MR, Zabucchi G, Sava G.

Anticancer Res. 2001 Jul-Aug;21(4A):2523-30.

PMID:
11724317

Supplemental Content

Support Center